AIM ImmunoTech
22 hedge funds and large institutions have $4.64M invested in AIM ImmunoTech in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 10 closing their positions.
218% more capital invested
Capital invested by funds: $1.46M → $4.64M (+$3.18M)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
10% more funds holding
Funds holding: 20 → 22 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.13M |
| 2 |
Morgan Stanley
New York
|
+$1.11M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$686K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$376K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$498K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$327K |
| 3 |
Jane Street
New York
|
-$72K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$56.6K |
| 5 |
Goldman Sachs
New York
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
26
HRT Financial
New York
| – | -$25K | -100 | Closed |
|
27
Victory Capital Management
San Antonio,
Texas
| – | -$22K | -87 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -20 | Closed |
|
|
S
29
SignatureFD
Atlanta,
Georgia
| – | -$1K | -5 | Closed |
|
|
VNA
30
Valley National Advisers
Bethlehem,
Pennsylvania
| – | -$1K | -5 | Closed |
|
AIM Hedge Fund Activity: Q2 2020 in Review
22 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2020, worth a combined $4.64M — up 218% from $1.46M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AIM positions and 10 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $1.13M. The largest seller was Millennium Management, exiting entirely with an estimated $498K sold.
- 22 institutional investors held AIM ImmunoTech (AIM) as of Q2 2020, up from 20 in Q1 2020.
- Funds reported $4.64M of AIM ImmunoTech stock for Q2 2020, up 218% quarter-over-quarter.
- 12 funds opened new AIM ImmunoTech positions in Q2 2020 and 10 closed out, a net change of +2 holders.
- The largest AIM ImmunoTech buyer in Q2 2020 was BlackRock, an estimated $1.13M added.
- The largest AIM ImmunoTech seller in Q2 2020 was Millennium Management, an estimated $498K sold.
Based on aggregated 13F filings for Q2 2020.